1. Home
  2. MBBC vs BOLD Comparison

MBBC vs BOLD Comparison

Compare MBBC & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MBBC

Marathon Bancorp Inc.

BUY

Current Price

$13.76

Market Cap

40.2M

Sector

Finance

ML Signal

BUY

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

HOLD

Current Price

$1.51

Market Cap

36.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
MBBC
BOLD
Founded
1902
2018
Country
United States
United States
Employees
35
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
40.2M
36.5M
IPO Year
N/A
2024

Fundamental Metrics

Financial Performance
Metric
MBBC
BOLD
Price
$13.76
$1.51
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$4.00
AVG Volume (30 Days)
12.0K
407.5K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.47
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.11
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.94
$0.96
52 Week High
$14.64
$1.78

Technical Indicators

Market Signals
Indicator
MBBC
BOLD
Relative Strength Index (RSI) 61.62 62.14
Support Level $12.93 $1.08
Resistance Level N/A $1.55
Average True Range (ATR) 0.41 0.09
MACD 0.07 0.02
Stochastic Oscillator 99.47 66.96

Price Performance

Historical Comparison
MBBC
BOLD

About MBBC Marathon Bancorp Inc.

Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: